IMV IPO year
What is the IPO year of IMV?
The IPO year of IMV, Inc. is 2012
What is the definition of IPO year?
Initial public offering is a type of public offering in which shares of a company usually are sold to institutional investors that in turn, sell to the general public, on a securities exchange, for the first time.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO year of companies in the Health Care sector on TSX compared to IMV
What does IMV do?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Companies with ipo year similar to IMV
- American Century ETF Trust has IPO year of 2011
- Sino Harbour has IPO year of 2011
- Horizons Gold Prod Equty Cvrd C has IPO year of 2011
- HFX has IPO year of 2011
- Dark Horse Resources has IPO year of 2011
- Om Metals Infraprojects has IPO year of 2011
- IMV has IPO year of 2012
- Evertec Inc has IPO year of 2013
- Virtus Health has IPO year of 2013
- Antero Resources Corp has IPO year of 2013
- Murphy USA Inc has IPO year of 2013
- Kodal Minerals Plc has IPO year of 2013
- Agios Pharmaceuticals Inc has IPO year of 2013